Comparing two approaches for treating acute colon cancer obstruction
Official title: Acute Colon Resection Versus Bridge to Colon Surgery With Stent or Stoma: a Prospective Cohort Study
Run by Skane University Hospital · NCT04450758 · Data updated 2026-11-12
This study is testing whether a two-step treatment for colon cancer obstruction, which involves using a stent or stoma, works better than immediate surgery in helping patients recover and live longer.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 100 Years |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Skane University Hospital Academic / other |
| Locations | 1 site (Gothenburg) |
| Status | Recruiting |
| Started | September 1, 2020 |
| Main results expected | December 31, 2029 |
| Study ends | December 31, 2031 |
| Registry record updated | April 23, 2026 |
| Trial ID | NCT04450758 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults over 18 years with symptomatic large bowel obstruction due to colon cancer requiring acute intervention.
✕Probably not a fit
Patients with colonic perforation, bleeding, or obstruction from causes other than colon cancer may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to evaluate the outcomes of primary resection versus a two-stage approach involving decompression with a stent or stoma for patients with malignant obstruction of the colon. The study will assess postoperative morbidity and mortality within 30 days, as well as long-term survival rates at 3 and 5 years. By comparing these two interventions, the researchers hope to determine if the two-stage procedure can lead to better short-term and long-term outcomes for patients. The study will include patients who are symptomatic and have CT-verified colon obstruction due to cancer.
Why it matters
Potential benefit: If successful, this study could lead to improved surgical outcomes and survival rates for patients with acute colon cancer obstruction.
How similar studies have gone: Previous studies have shown promising results with similar two-stage approaches in managing malignant bowel obstructions, suggesting potential for success in this study.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \>18 years * Symptomatic large bowel obstruction requiring acute intervention * CT-verified colon obstruction due to colon cancer independent of presence of metastases * Informed consent Exclusion Criteria: * Colonic perforation or bleeding * Colonic obstruction of other origin than colon cancer * Palliative situation
Where it's running
-
Göteborg University
Gothenburg, Sweden Recruiting
Study contacts
- Principal investigator: Pamela Buchwald, PhD MD — Skåne University Hospital, Lund University
- Study coordinator: Pamela Buchwald, PhD MD
- Email: pamela.buchwald@med.lu.se
- Phone: 004640331000
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
LTZ-232: a first-in-human test in advanced colorectal and other solid tumors
A first-in-human study tests LTZ-232, a new therapy for adults with unresectable or metastatic colorectal cancer and other solid tumors that have not responded to standard treatments.
-
ctDNA-Guided Immunotherapy for dMMR/MSI-H Colon Cancer
This study tests whether tracking ctDNA can guide neoadjuvant immunotherapy and surgical decisions for people with dMMR/MSI-H colon cancer, using PD-1 inhibitors first and adding CTLA-4 inhibitors if ctDNA remains detectable.
-
Tafolecimab with chemoimmunotherapy as neoadjuvant treatment for locally advanced colon cancer
This study tests whether adding tafolecimab to a chemoimmunotherapy regimen helps shrink locally advanced colon cancer before surgery in adults who have pMMR/MSS tumors.
-
Neoadjuvant pembrolizumab and porustobart for resectable MSS colon cancer
This trial tests whether giving pembrolizumab with porustobart before surgery can shrink MSS colon cancer and improve outcomes, comparing one versus two doses of porustobart.
-
DEM301 in advanced colorectal cancer: a first-in-human test
This first-in-human Phase 1 study tests DEM301 in adults with advanced metastatic colorectal cancer to see if it is safe, how it behaves in the body, and whether it shows any signs of activity.
-
SHY-ONC6: a new anti-cancer drug tested in adults with advanced solid tumors
This early-phase study tests SHY-ONC6 to see if it is safe and can help people with advanced solid tumors after standard therapies have failed.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.